Sandbox Reserved 430

Introduction

The goal of pharmaceuticals is to prevent or cure disease through drug therapy by specifically targeting cells, proteins, enzymes, genes, etc. It is often crucial to understand the structure, function, and relevant mechanisms involved with the target when designing an effective drug candidate. Furthermore, being able to know the effects on structure after drug-binding can provide insight into the functionality of a specific target. Through crystal structure analysis of P2Y12 binded to AZD1283, differences in secondary and tertiary structure can be observed with and without the small molecule. This structural modifications support proposed mechanisms of active P2Y12 and provide a basis for future drug candidates.

P2Y12 is a G-protein-coupled receptor (GPCR) found on blood platelets. As a GPCR, P2Y12 responds to concentrations of adenosine diphosphate in the extracellular matrix. This leads to purinergic signal transduction and ultimately cellular response. Being located on blood platelets, activated P2Y12 receptors induce platelet activation and clotting. Drugs, such as clopidogrel, ticagrelor, and ticlopidine, are designed to inhibit P2Y12 activation by altering the receptor active site through secondary and tertiary structure modification. Successful inhibition of P2Y12 corresponds to decreased platelet activation, a helpful tool in prevention of stroke and heart attacks. Additionally, P2Y12-specific drugs can be used in treating cardiovascular disease.

Here, image analysis of P2Y12 crystals are used to model protein structure in complex with AstraZeneca’s novel ADZ1283: Ethyl 6-(4(-((benzylsulphonyl)carbamoyl)piperidin-1yl)-5-cyano-2-methylnicotinate. ADZ1283 functions to block the P2Y12 receptor as a means to treat thrombosis. ADZ1283-binding leads to unique protein structure, unfound in other P2Y receptors. Helix V of seven transmembrane helices is found to be . This change along with the discovery of a potential second active within P2Y12 has implications on how P2Y12 uses it’s seven transmembrane helical bundle interact with ADP in the bloodstream.

a view of the Anionic Side Chains in red and charged nucleic acids and ligands in grey.

Overall Structure

The is made up of eight alpha helices. There are seven transmembrane alpha helices and a carboxy-terminal helix VII, which is parallel to the membrane bilayer. There is only one disulphide bond the amino terminus with helix VII Helix V: straight conformation because there are no proline or glycine residues to destabilize its structure

- Polar vs nonpolar: Polar regions are pink. Nonpolar, or hydrophobic, regions are grey.

-N to C termini:

The protein shown in displays the the N and C termini

Binding Interactions

The of P2Y12 is colored in purple, and the ligand (AZD1283) is colored in yellow. The binding site for AZD1283, pocket 1, is composed of helices III–VII, while pocket II contains helices I-III and VII is not represented here. The two pockets are separated by two residues, Y1053 and K2807, which makes the pocket II not a binding site for AZD1283. With the observation of the AZD1283-bound P2Y12R with residue C97 belong to pocket 2, the active metabolites drugs might occupy this pocket.

Additional Features

Acute coronary syndrome, a condition in which there is sudden blockage of blood flow to the heart, is majorly caused by a disease known as atherothrombosis. This disease is characterized by blocked arteries due to thrombosis: formation of a clot within a blood vessel. The P2Y12 protein is an important platelet receptor inhibitor that can be combined with aspirin in the management of ACS. It regulates certain functions through purinergic signaling, which is a form of extracellular signaling mediated by purine nucleotides and nucleosides like ADP and ATP.

The P2Y12 receptor is mainly found on the surface of blood platelets, and functions as a regulator in platelet activation and therefore blood clotting. The P2Y12 receptor is a G-protein coupled receptor, a seven-transmembrane domain protein linked to the cAMP-signaling pathway. It mediates platelet activation by decreasing intracellular cAMP levels through inhibition of an AC-mediated signaling pathway. Acting as a chemoreceptor, P2Y12 utilizes ADP as an agonist, which initiates ADP-induced platelet aggregation. Clopidogrel in covalent binding complex with P2Y12 acts as an antiplatelet agent, specifically as an ADP receptor inhibitor to decrease platelet aggregation and inhibit thrombus formation.

Clopidogrel is a pro-drug and thienopyridine-type inhibitor of the P2Y12 receptor, which requires Cytochrome P450 to hepatically transform it to exert its anti platelet effect. to see this interaction between the P450 complex and Clopidogrel.

Quiz Question 1

What other residues can be used to replace the ?

See Also

• 4ntj
• 4pxz
• 4py0
• 1vz1

Credits

Introduction - Adam Murphy

Overall Structure - Cora Ricker

Drug Binding Site - Duy Nguyen

Additional Features - Lauren Timmins

Quiz Question 1 - Aidan Finnerty

References

1. ↑ Zhang K, Zhang J, Gao ZG, Zhang D, Zhu L, Han GW, Moss SM, Paoletta S, Kiselev E, Lu W, Fenalti G, Zhang W, Muller CE, Yang H, Jiang H, Cherezov V, Katritch V, Jacobson KA, Stevens RC, Wu B, Zhao Q. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature. 2014 May 1;509(7498):115-8. doi: 10.1038/nature13083. Epub 2014 Mar 23. PMID:24670650 doi:http://dx.doi.org/10.1038/nature13083